Exploring the Neuroprotective Potential of CBD in Preventing Oxaliplatin-Induced Neuropathy: A Prospective Study

Research Inst Of Fox Chase Can Ctr, Philadelphia PA

Investigators

Abstract

Project Summary The project titled “Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study” will evaluate the feasibility of a hemp-based cannabinoid (CBD) related intervention in colorectal cancer (CRC) patients undergoing oxaliplatin based chemotherapy and generate preliminary data on its ability to provide potential neuroprotective benefits and reduce/prevent incidence of chemotherapy-induced neuropathy (CIPN). Additionally, we will also be exploring the expression of inflammatory markers and miRNA in oxaliplatin treated patients and comparing between the groups that received a CBD intervention versus those who did not to understand the biological rationale of the neuroprotective effect of CBD. In aim 1, we will investigate the feasibility and acceptability of incorporating hemp-based CBD supplementation as a supportive therapy during Ox-based chemotherapy for CRC patients. We will also study the rates of acute and chronic Ox induced Peripheral Neuropathy (OIPN) and other treatment related adverse events in patients treated with Hemp based CBD and Ox based chemotherapy and compare them to rates seen among patients who get standard therapy. In aim 2, we will determine differentially expressed inflammatory markers and miRNA in patients treated with Ox with or without CBD treatment. To conduct this work, we assembled a team with expertise in clinical and basic science of colorectal cancer and cannabinoid research with a strong record of accomplishment of collaborations and innovations. Our study will pave the way for larger randomized trials that will aid in understanding the potential benefits of CBD supplementation in managing OIPN and associated adverse effects.